Severe or Fatal Liver Injury in 50 Patients in the United States Taking Rifampin and Pyrazinamide for Latent Tuberculosis Infection
Open Access
- 1 February 2006
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 42 (3) , 346-355
- https://doi.org/10.1086/499244
Abstract
Background. Severe liver injuries were attributed to the rifampin and pyrazinamide (RZ) regimen after it was recommended for treating latent tuberculKeywords
This publication has 19 references indexed in Scilit:
- Targeted Tuberculin Testing and Treatment of Latent Tuberculosis InfectionAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Rifampin and Pyrazinamide vs Isoniazid for Prevention of Tuberculosis in HIV-Infected PersonsAn International Randomized TrialJAMA, 2000
- Twice weekly tuberculosis preventive therapy in HIV infection in ZambiaAIDS, 1998
- Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infectionThe Lancet, 1998
- Hepatotoxicity of Antitubercular TreatmentsDrug Safety, 1996
- Liver injury during antituberculosis treatment: An 11-year studyTubercle and Lung Disease, 1996
- Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazidHepatology, 1995
- Isoniazid-associated Hepatitis Deaths: A Review of Available InformationAmerican Review of Respiratory Disease, 1992
- Fulminant hepatitis during treatment with Rifampicin, pyrazinamid and ethambutolEuropean Journal of Pediatrics, 1987
- Isoniazid-Associated HepatitisAmerican Review of Respiratory Disease, 1972